School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

ABEONA THERAPEUTICS INC. ABEO

Healthcare · Biotechnology

$4.90last close 2026-10-12 · market cap $280.20M · delayed data

Trailing returns

1M-9.59%
3M-29.80%
6M-0.20%
1Y-8.58%
5Y-78.22%

Basis: Adjusted daily closes.

What it does

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.

Open ABEO in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies